Comparative Pharmacology
Head-to-head clinical analysis: GARAMYCIN versus TOBRAMYCIN SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GARAMYCIN versus TOBRAMYCIN SULFATE.
GARAMYCIN vs TOBRAMYCIN SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gentamicin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis, leading to bacterial cell death.
Aminoglycoside antibiotic; binds to 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis.
Gentamicin 3-5 mg/kg/day IV or IM in 3 divided doses every 8 hours for serious infections; may use once-daily dosing (5 mg/kg IV every 24 hours) for certain indications.
Adults: Tobramycin 3-5 mg/kg/day IV divided every 8 hours, or 5-7 mg/kg/day IV once daily. For inhalation: 300 mg nebulized twice daily.
None Documented
None Documented
Terminal elimination half-life: 2-3 hours in adults with normal renal function; prolonged in renal impairment (up to 40-50 hours in anuria).
Terminal elimination half-life is 2-3 hours in patients with normal renal function; extends to 24-100 hours in severe renal impairment (CrCl <10 mL/min), requiring dose adjustment.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine within 24 hours. Minimal biliary/fecal elimination (<2%).
Primarily renal (glomerular filtration) with 90-95% excreted unchanged in urine within 24 hours; biliary/fecal <1%.
Category C
Category D/X
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic